Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.

Autor: Nahon S; Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France., Rastkhah M; Centre d'Hémato-Cancérologie Praz-Coutant, Passy, France., Ben Abdelghani M; Centre Paul Strauss, Strasbourg, France., Soumoudronga RF; Sandoz Biopharmaceuticals, 49, Avenue Georges Pompidou, 92593, Levallois-Perret, Cedex, France., Gasnereau I; Sandoz Biopharmaceuticals, 49, Avenue Georges Pompidou, 92593, Levallois-Perret, Cedex, France. isabelle.gasnereau@sandoz.com., Labourey JL; Centre Hospitalier, Carcassonne, France.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2016 May; Vol. 24 (5), pp. 1991-1998. Date of Electronic Publication: 2015 Oct 27.
DOI: 10.1007/s00520-015-2986-0
Abstrakt: Purpose: Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio(®)-biosimilar of Neupogen(®) (G-CSF; filgrastim)-in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients.
Methods: We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy.
Results: One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio(®) were pain, in particular bone pain. No serious adverse event related to Zarzio(®) was reported.
Conclusion: The results obtained in real-life conditions confirm that Zarzio(®) is efficient and well tolerated in cancer patients.
Databáze: MEDLINE
Externí odkaz: